Anti-CD28 x Anti-CD3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD28 and anti-CD3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can improve T-cell activation. It is designed for the research of Tumors therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY